Standard

Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies : surveillance after vaccination. / Fresco-Taboada, Alba; García-Durán, Marga; Aira, Cristina; López, Lissett; Sastre, Patricia; van der Hoek, Lia; van Gils, Marit J.; Brouwer, Philip J. M.; Sanders, Rogier W.; Holzer, Barbara; Zimpernikc, Irene; López-Collazo, Eduardo; Muñoz, Patricia; Rueda, Paloma; Vela, Carmen.

In: Diagnostic microbiology and infectious disease, Vol. 102, No. 4, 115650, 04.2022.

Research output: Contribution to journalArticleAcademicpeer-review

Harvard

Fresco-Taboada, A, García-Durán, M, Aira, C, López, L, Sastre, P, van der Hoek, L, van Gils, MJ, Brouwer, PJM, Sanders, RW, Holzer, B, Zimpernikc, I, López-Collazo, E, Muñoz, P, Rueda, P & Vela, C 2022, 'Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination', Diagnostic microbiology and infectious disease, vol. 102, no. 4, 115650. https://doi.org/10.1016/j.diagmicrobio.2022.115650

APA

Fresco-Taboada, A., García-Durán, M., Aira, C., López, L., Sastre, P., van der Hoek, L., van Gils, M. J., Brouwer, P. J. M., Sanders, R. W., Holzer, B., Zimpernikc, I., López-Collazo, E., Muñoz, P., Rueda, P., & Vela, C. (2022). Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination. Diagnostic microbiology and infectious disease, 102(4), [115650]. https://doi.org/10.1016/j.diagmicrobio.2022.115650

Vancouver

Fresco-Taboada A, García-Durán M, Aira C, López L, Sastre P, van der Hoek L et al. Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination. Diagnostic microbiology and infectious disease. 2022 Apr;102(4). 115650. https://doi.org/10.1016/j.diagmicrobio.2022.115650

Author

Fresco-Taboada, Alba ; García-Durán, Marga ; Aira, Cristina ; López, Lissett ; Sastre, Patricia ; van der Hoek, Lia ; van Gils, Marit J. ; Brouwer, Philip J. M. ; Sanders, Rogier W. ; Holzer, Barbara ; Zimpernikc, Irene ; López-Collazo, Eduardo ; Muñoz, Patricia ; Rueda, Paloma ; Vela, Carmen. / Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies : surveillance after vaccination. In: Diagnostic microbiology and infectious disease. 2022 ; Vol. 102, No. 4.

BibTeX

@article{502fe28c6dc64176b16e7f5a08a561fa,
title = "Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination",
abstract = "Massive vaccination programs are being carried out to limit the SARS-CoV-2 pandemic that started in December 2019. Serological tests are of major importance as an indicator of circulation of the virus and to assess how vaccine-induced immunity progresses. An Enzyme-Linked Immunosorbent Assay (ELISA) and a Lateral Flow Assay (LFA) have been developed based on the SARS-CoV-2 recombinant Receptor Binding Domain (RBD) and the combination of Spike and Nucleoprotein, respectively. The validation with 1272 serum samples by comparison with INgezim COVID 19 DR showed good diagnostic performance (sensitivity: 93.2%-97.2%; specificity: 98.3%-99.3%) for detection of previous contact with SARS-CoV-2. Moreover, according to our results, these assays can help in the serosurveillance during and after vaccination, by detecting the humoral immune response as soon as 15 days postvaccination and identifying low-respondents. Hence, these tests could play a key role in the progression to a COVID-19 free world, helping to adjust future vaccination protocols.",
keywords = "COVID-19, RBD, SARS-CoV-2, Serology, Spike protein, Vaccination",
author = "Alba Fresco-Taboada and Marga Garc{\'i}a-Dur{\'a}n and Cristina Aira and Lissett L{\'o}pez and Patricia Sastre and {van der Hoek}, Lia and {van Gils}, {Marit J.} and Brouwer, {Philip J. M.} and Sanders, {Rogier W.} and Barbara Holzer and Irene Zimpernikc and Eduardo L{\'o}pez-Collazo and Patricia Mu{\~n}oz and Paloma Rueda and Carmen Vela",
note = "Funding Information: This work was partially funded by the Dutch government within the PPP project: RAPAPA (Rapid point of care tests to detect COVID-19 patients). Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
month = apr,
doi = "10.1016/j.diagmicrobio.2022.115650",
language = "English",
volume = "102",
journal = "Diagnostic microbiology and infectious disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "4",

}

RIS

TY - JOUR

T1 - Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies

T2 - surveillance after vaccination

AU - Fresco-Taboada, Alba

AU - García-Durán, Marga

AU - Aira, Cristina

AU - López, Lissett

AU - Sastre, Patricia

AU - van der Hoek, Lia

AU - van Gils, Marit J.

AU - Brouwer, Philip J. M.

AU - Sanders, Rogier W.

AU - Holzer, Barbara

AU - Zimpernikc, Irene

AU - López-Collazo, Eduardo

AU - Muñoz, Patricia

AU - Rueda, Paloma

AU - Vela, Carmen

N1 - Funding Information: This work was partially funded by the Dutch government within the PPP project: RAPAPA (Rapid point of care tests to detect COVID-19 patients). Publisher Copyright: © 2022 Elsevier Inc.

PY - 2022/4

Y1 - 2022/4

N2 - Massive vaccination programs are being carried out to limit the SARS-CoV-2 pandemic that started in December 2019. Serological tests are of major importance as an indicator of circulation of the virus and to assess how vaccine-induced immunity progresses. An Enzyme-Linked Immunosorbent Assay (ELISA) and a Lateral Flow Assay (LFA) have been developed based on the SARS-CoV-2 recombinant Receptor Binding Domain (RBD) and the combination of Spike and Nucleoprotein, respectively. The validation with 1272 serum samples by comparison with INgezim COVID 19 DR showed good diagnostic performance (sensitivity: 93.2%-97.2%; specificity: 98.3%-99.3%) for detection of previous contact with SARS-CoV-2. Moreover, according to our results, these assays can help in the serosurveillance during and after vaccination, by detecting the humoral immune response as soon as 15 days postvaccination and identifying low-respondents. Hence, these tests could play a key role in the progression to a COVID-19 free world, helping to adjust future vaccination protocols.

AB - Massive vaccination programs are being carried out to limit the SARS-CoV-2 pandemic that started in December 2019. Serological tests are of major importance as an indicator of circulation of the virus and to assess how vaccine-induced immunity progresses. An Enzyme-Linked Immunosorbent Assay (ELISA) and a Lateral Flow Assay (LFA) have been developed based on the SARS-CoV-2 recombinant Receptor Binding Domain (RBD) and the combination of Spike and Nucleoprotein, respectively. The validation with 1272 serum samples by comparison with INgezim COVID 19 DR showed good diagnostic performance (sensitivity: 93.2%-97.2%; specificity: 98.3%-99.3%) for detection of previous contact with SARS-CoV-2. Moreover, according to our results, these assays can help in the serosurveillance during and after vaccination, by detecting the humoral immune response as soon as 15 days postvaccination and identifying low-respondents. Hence, these tests could play a key role in the progression to a COVID-19 free world, helping to adjust future vaccination protocols.

KW - COVID-19

KW - RBD

KW - SARS-CoV-2

KW - Serology

KW - Spike protein

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85125115958&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2022.115650

DO - 10.1016/j.diagmicrobio.2022.115650

M3 - Article

C2 - 35218991

VL - 102

JO - Diagnostic microbiology and infectious disease

JF - Diagnostic microbiology and infectious disease

SN - 0732-8893

IS - 4

M1 - 115650

ER -

ID: 21861589